Tags

Type your tag names separated by a space and hit enter

Case-control study of phyto-oestrogens and breast cancer.
Lancet. 1997 Oct 04; 350(9083):990-4.Lct

Abstract

BACKGROUND

Phyto-oestrogens are a group of naturally occurring chemicals derived from plants; they have a structure similar to oestrogen, and form part of our diet. They also have potentially anticarcinogenic biological activity. We did a case-control study to assess the association between phyto-oestrogen intake (as measured by urinary excretion) and the risk of breast cancer.

METHODS

Women with newly diagnosed early breast cancer were interviewed by means of questionnaires, and a 72 h urine collection and blood sample were taken before any treatment started. Controls were randomly selected from the electoral roll after matching for age and area of residence. 144 pairs were included for analysis. The urine samples were assayed for the isoflavonic phyto-oestrogens daidzein, genistein, and equol, and the lignans enterodiol, enterolactone, and matairesinol.

FINDINGS

After adjustment for age at menarche, parity, alcohol intake, and total fat intake, high excretion of both equol and enterolactone was associated with a substantial reduction in breast-cancer risk, with significant trends through the quartiles: equol odds ratios were 1.00, 0.45 (95% CI 0.20, 1.02), 0.52 (0.23, 1.17), and 0.27 (0.10, 0.69)--trend p = 0.009--and enterolactone odds ratios were 1.00, 0.91 (0.41, 1.98), 0.65 (0.29, 1.44), 0.36 (0.15, 0.86)--trend p = 0.013. For most other phytoestrogens there was a reduction in risk, but it did not reach significance. Difficulties with the genistein assay precluded analysis of that substance.

INTERPRETATION

There is a substantial reduction in breast-cancer risk among women with a high intake (as measured by excretion) of phyto-oestrogens-particularly the isoflavonic phyto-oestrogen equol and the lignan enterolactone. These findings could be important in the prevention of breast cancer.

Authors+Show Affiliations

University Department of Surgery, Queen Elizabeth II Medical Centre, Perth, Western Australia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9329514

Citation

Ingram, D, et al. "Case-control Study of Phyto-oestrogens and Breast Cancer." Lancet (London, England), vol. 350, no. 9083, 1997, pp. 990-4.
Ingram D, Sanders K, Kolybaba M, et al. Case-control study of phyto-oestrogens and breast cancer. Lancet. 1997;350(9083):990-4.
Ingram, D., Sanders, K., Kolybaba, M., & Lopez, D. (1997). Case-control study of phyto-oestrogens and breast cancer. Lancet (London, England), 350(9083), 990-4.
Ingram D, et al. Case-control Study of Phyto-oestrogens and Breast Cancer. Lancet. 1997 Oct 4;350(9083):990-4. PubMed PMID: 9329514.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Case-control study of phyto-oestrogens and breast cancer. AU - Ingram,D, AU - Sanders,K, AU - Kolybaba,M, AU - Lopez,D, PY - 1997/11/5/pubmed PY - 1997/11/5/medline PY - 1997/11/5/entrez SP - 990 EP - 4 JF - Lancet (London, England) JO - Lancet VL - 350 IS - 9083 N2 - BACKGROUND: Phyto-oestrogens are a group of naturally occurring chemicals derived from plants; they have a structure similar to oestrogen, and form part of our diet. They also have potentially anticarcinogenic biological activity. We did a case-control study to assess the association between phyto-oestrogen intake (as measured by urinary excretion) and the risk of breast cancer. METHODS: Women with newly diagnosed early breast cancer were interviewed by means of questionnaires, and a 72 h urine collection and blood sample were taken before any treatment started. Controls were randomly selected from the electoral roll after matching for age and area of residence. 144 pairs were included for analysis. The urine samples were assayed for the isoflavonic phyto-oestrogens daidzein, genistein, and equol, and the lignans enterodiol, enterolactone, and matairesinol. FINDINGS: After adjustment for age at menarche, parity, alcohol intake, and total fat intake, high excretion of both equol and enterolactone was associated with a substantial reduction in breast-cancer risk, with significant trends through the quartiles: equol odds ratios were 1.00, 0.45 (95% CI 0.20, 1.02), 0.52 (0.23, 1.17), and 0.27 (0.10, 0.69)--trend p = 0.009--and enterolactone odds ratios were 1.00, 0.91 (0.41, 1.98), 0.65 (0.29, 1.44), 0.36 (0.15, 0.86)--trend p = 0.013. For most other phytoestrogens there was a reduction in risk, but it did not reach significance. Difficulties with the genistein assay precluded analysis of that substance. INTERPRETATION: There is a substantial reduction in breast-cancer risk among women with a high intake (as measured by excretion) of phyto-oestrogens-particularly the isoflavonic phyto-oestrogen equol and the lignan enterolactone. These findings could be important in the prevention of breast cancer. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/9329514/Case_control_study_of_phyto_oestrogens_and_breast_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(97)01339-1 DB - PRIME DP - Unbound Medicine ER -